Reported about 13 hours ago
Recursion Pharmaceuticals (NASDAQ:RXRX) saw a remarkable 20.13% increase in its stock price on Friday, closing at $5.49. This surge was driven by the announcement of Boltz-2, a next-generation AI model designed to predict binding affinity more effectively than earlier models. Powered by NVIDIA supercomputing technology, Boltz-2 aims to enhance drug discovery by allowing research teams to identify promising compounds with unprecedented speed and accuracy.
Source: YAHOO